Copyright © Inderes 2011 - present. All rights reserved.

Genovis

17.36 SEK

+2.00 %

1,633 following

GENO

First North Stockholm

Biotechnology & Pharmaceuticals

Health Care

+2.00 %
-20.00 %
-18.31 %
-13.20 %
-26.75 %
-40.24 %
-74.51 %
-59.20 %
-36.59 %

Genovis operates in biotechnology. The main focus is on the development of enzymes used in various pharmaceuticals. The company's patented NIMT technology is developed to facilitate the LifeScience industry to conduct preclinical research. The company's products are resold under several brands. Genovis was established in 1999 and is headquartered in Lund.

Read more
Market cap
1.15B SEK
Turnover
407.03K SEK
Revenue
128.95M
EBIT %
16.5 %
P/E
48.22
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
28.4
2026

Interim report Q1'26

18.5
2026

General meeting '26

23.7
2026

Interim report Q2'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Redeye analyzed the Q4 results, now that the stock valuation is about 28, the views are: Bear 24, Base 53 Bull 104 redeye.se Genovis Q4 2024: Initial take Redeye's provides its initial take on Genovis' year-end report which came in softer than we had estimated, albeit still showing...
2/15/2025, 10:16 AM
by veronmaksaja
7
Q4 MFN – 14 Feb 25 Genovis: Strong momentum: 21% growth in enzyme business and signifi... October – December 2024 Net sales totaled SEK 27,936 (23,118) thousand, with a growth rate of 21%, including when adjusted for currency effects. Net sales, including the divested Antibody Busines...
2/14/2025, 7:25 AM
by sillinkutoja
7
MFN – 24 Jul 25 Genovis Expands License Agreement to Access Proprietary Enzyme Tech... Genovis AB, a leading provider of innovative enzyme technologies, today announced an expansion of its license agreement with Thermo Fisher Scientific to gain access to proprietary enzyme technology...
7/24/2025, 6:32 AM
by sillinkutoja
6
Genovis also published its results: investor.genovis.com Genovis Investor Relations » Genovis AB Interim report January – March 2025 And it went well, with record sales in enzymes. Revenue exceeded the analyst’s forecast by 13%, results roughly in line with expectations. A strengthened...
5/23/2025, 10:38 AM
by Von Wangell
6
They should really get that Xork licensed somewhere. I haven’t heard of any breakthroughs in AAV gene therapies this year. But it’s not an abandoned area yet.
5/23/2025, 10:50 AM
by Clark kent
3
When a well-performing company’s valuation is stuck in the lower leagues, the question arises when the big players will come and snatch a tasty morsel from the ecosystem. I had a discussion with Claude.ai about what kind of acquisition opportunities and ambitions Genovis evokes. ...
6/10/2025, 6:25 PM
by LeBaron
2
ChatGPT rumors immediately fell flat. Genovis -16%. Artificial intelligence is quite a humbug in information dissemination. The more people ask it for financial advice, the muddier it gets.
2/3/2025, 10:20 AM
by Tokarczuk
2
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.